AR079174A1 - Composiciones para comprimidos desintegrables oralmente de ondansetron para prevenir nauseas y vomitos - Google Patents

Composiciones para comprimidos desintegrables oralmente de ondansetron para prevenir nauseas y vomitos

Info

Publication number
AR079174A1
AR079174A1 ARP100104426A ARP100104426A AR079174A1 AR 079174 A1 AR079174 A1 AR 079174A1 AR P100104426 A ARP100104426 A AR P100104426A AR P100104426 A ARP100104426 A AR P100104426A AR 079174 A1 AR079174 A1 AR 079174A1
Authority
AR
Argentina
Prior art keywords
blocking agent
serotonin
patients
weakly basic
ondansetron
Prior art date
Application number
ARP100104426A
Other languages
English (en)
Inventor
Gopi M Venkatesh
Original Assignee
Eurand Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Inc filed Critical Eurand Inc
Publication of AR079174A1 publication Critical patent/AR079174A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion farmacéutica en forma de un comprimido oralmente desintegrable comodo para el paciente que comprende un agente bloqueador selectivo de serotonina 5-HT3 débilmente básico para prevenir náuseas y/o vomitos durante hasta 24 horas después de la dosificacion, por ejemplo en pacientes con cáncer antes de someterse a quimioterapia moderadamente emetogénica o radioterapia corporal total o parcial o en sujetos con riesgo entre moderado y alto de sufrir náuseas y/o vomitos postoperatorios o post-alta antes de cirugías ambulatorias en pacientes hospitalizados o no hospitalizados. La forma de dosificacion unitaria comprende multiples partículas de fármaco de liberacion inmediata que proporcionan perfiles de disolucion similares a los del producto de fármaco de referencia, y una o más poblaciones de perlas de liberacion pulsátil gradual, comprendiendo al menos un ácido orgánico, que solubiliza dicho agente bloqueador selectivo de serotonina 5-HT3 débilmente básico antes de liberarlo en el ambiente intestinal hostil, en donde el agente bloqueador es prácticamente insoluble, es capaz de administrar dicho agente antiemético en pacientes que lo necesitan en un modo de liberacion sostenida que es adecuado para un régimen de dosificacion de una vez al día. Reivindicacion 12: El ODT de la reivindicacion 1, en donde dicho agente bloqueador selectivo de serotonina 5-HT3 débilmente básico se selecciona del grupo que consiste de ondansetron, tropisetron, granisetron, dolasetron, palonosetron, ramosetron, y sales y/o solvatos farmacéuticamente aceptables de los mismos.
ARP100104426A 2009-11-30 2010-11-30 Composiciones para comprimidos desintegrables oralmente de ondansetron para prevenir nauseas y vomitos AR079174A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26523309P 2009-11-30 2009-11-30

Publications (1)

Publication Number Publication Date
AR079174A1 true AR079174A1 (es) 2011-12-28

Family

ID=43989727

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104426A AR079174A1 (es) 2009-11-30 2010-11-30 Composiciones para comprimidos desintegrables oralmente de ondansetron para prevenir nauseas y vomitos

Country Status (8)

Country Link
US (1) US20110135724A1 (es)
EP (1) EP2506714A4 (es)
AR (1) AR079174A1 (es)
BR (1) BR112012013011A2 (es)
CA (1) CA2782163A1 (es)
TW (1) TW201127827A (es)
UY (1) UY33061A (es)
WO (1) WO2011066289A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5919173B2 (ja) * 2012-11-22 2016-05-18 全星薬品工業株式会社 徐放性塩酸アンブロキソール口腔内崩壊錠
WO2014181195A2 (en) * 2013-03-14 2014-11-13 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms
JP6215443B2 (ja) 2013-03-15 2017-10-18 マース インコーポレーテッドＭａｒｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 特発性嘔吐を予防、低減、緩和または治療する組成物および方法
WO2014143539A1 (en) * 2013-03-15 2014-09-18 The Iams Company Composition and method for preventing, reducing, alleviating, or treating idiopathic vomiting
US20180256515A1 (en) 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition
EP3813831B1 (en) * 2018-09-21 2023-03-22 Amneal Complex Products Research LLC Extended release compositions comprising trihexyphenidyl
US11045420B2 (en) * 2018-09-21 2021-06-29 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising trihexyphenidyl
US11154505B1 (en) * 2021-02-03 2021-10-26 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising trihexyphenidyl

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
CA2640382C (en) * 2006-01-27 2015-12-29 Eurand, Inc Drug delivery systems comprising weakly basic drugs and organic acids
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions

Also Published As

Publication number Publication date
WO2011066289A1 (en) 2011-06-03
UY33061A (es) 2011-02-28
TW201127827A (en) 2011-08-16
EP2506714A4 (en) 2013-07-03
CA2782163A1 (en) 2011-06-03
EP2506714A1 (en) 2012-10-10
US20110135724A1 (en) 2011-06-09
BR112012013011A2 (pt) 2015-09-08

Similar Documents

Publication Publication Date Title
AR079174A1 (es) Composiciones para comprimidos desintegrables oralmente de ondansetron para prevenir nauseas y vomitos
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
JP2014040437A5 (es)
JP2010525050A5 (es)
JP2015038135A5 (es)
HRP20240082T1 (hr) Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
JP2009539769A5 (es)
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
JP2019511526A5 (es)
PA8855101A1 (es) Formulaciones de imiquimod de menor potencia de dosificación y regímenes de dosificación cortos para tratar queratosis actínica
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
MY189110A (en) Fast acting orally disintegrating film
JP2019511529A5 (es)
JP2019530706A5 (es)
AR078170A1 (es) Metodos para el tratamiento de tumores cerebrales
JP2014504636A5 (es)
JP2012505830A5 (es)
HRP20161796T1 (hr) Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice
CO6180495A2 (es) Formulacion de medicamento liquida
NZ611026A (en) Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
JP2020512408A5 (es)
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite

Legal Events

Date Code Title Description
FB Suspension of granting procedure